{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:24:22Z","timestamp":1789208662599,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.critrevonc.2012.09.008","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T06:11:55Z","timestamp":1350972715000},"page":"42-51","source":"Crossref","is-referenced-by-count":46,"title":["The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy"],"prefix":"10.1016","volume":"86","author":[{"given":"Vincenza","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Tartarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2012.09.008_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0010","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.09.008_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/clc.20823","article-title":"Cardio-oncology\/onco-cardiology","volume":"33","author":"Hong","year":"2010","journal-title":"Clinical Cardiology"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.09.008_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2009.09.005","article-title":"Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults","volume":"73","author":"Droz","year":"2010","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.09.008_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0035","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0040","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0045","article-title":"Association of Radiotherapy and Oncology of the Mediterranean area: controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care","volume":"May","author":"Bud\u00e4us","year":"2011","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.09.008_bib0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4329\/wjr.v4.i6.241","article-title":"Epidemiology of prostate cancer and treatment remarks","volume":"4","author":"Arcangeli","year":"2012","journal-title":"World Journal of Radiology"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.09.008_bib0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2009.05.001","article-title":"Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.09.008_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0065","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.ju.0000107247.81471.06","article-title":"The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry","volume":"171","author":"Cooperberg","year":"2004","journal-title":"Journal of Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2407-12-54","article-title":"Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review","volume":"12","author":"Sasse","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0080","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0085","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.09.008_bib0090","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0095","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.critrevonc.2006.06.006","article-title":"Long-term side effects of ADT in men with non-metastatic prostate cancer: a systematic literature review","volume":"60","author":"Alibhai","year":"2006","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0105","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of longterm adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0110","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0115","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.09.008_bib0125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"European Urology"},{"issue":"24","key":"10.1016\/j.critrevonc.2012.09.008_bib0130","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0135","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1442-2042.2008.02074.x","article-title":"The role of testosterone in the pathogenesis of prostate cancer","volume":"15","author":"Imamoto","year":"2008","journal-title":"International Journal of Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ncponc0765","article-title":"Drug Insight: role of the androgen receptor in the development and progression of prostate cancer","volume":"4","author":"Taplin","year":"2007","journal-title":"Nature Clinical Practice \u2013 Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"62","author":"Harris","year":"2009","journal-title":"Nature Clinical Practice \u2013 Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0155","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jc.87.2.599","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.09.008_bib0165","first-page":"332","article-title":"Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care","volume":"35","author":"Collins","year":"2012","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0170","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0175","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/gerona\/58.12.M1103","article-title":"The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action","volume":"58","author":"Bhasin","year":"2003","journal-title":"Journals of Gerontology Series A: Biological Sciences and Medical Sciences"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2164\/jandrol.108.005751","article-title":"The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance","volume":"30","author":"Traish","year":"2009","journal-title":"Journal of Andrology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","article-title":"Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer","volume":"71","author":"Smith","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0190","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0195","first-page":"687","article-title":"Endocrine complications of androgen deprivation therapy in men with prostate cancer","volume":"4","author":"Harle","year":"2006","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.09.008_bib0200","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2007-2595","article-title":"Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis","volume":"93","author":"Shahani","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clinical Science (London)"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","article-title":"Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia","volume":"154","author":"Eri","year":"1995","journal-title":"Journal of Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0215","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0220","series-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation","author":"World Health Organization","year":"1999"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0225","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0230","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2004.04.054","article-title":"Testosterone is a potent inhibitor of L-type Ca(2+) channels","volume":"318","author":"Scragg","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0235","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/hrt.2003.021121","article-title":"Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life","volume":"90","author":"Malkin","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/CS20020209","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clinical Science"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.09.008_bib0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/er.2003-0005","article-title":"Androgens and cardiovascular disease","volume":"24","author":"Liu","year":"2003","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0250","first-page":"2012","article-title":"Connecting the lines between hypogonadism and atherosclerosis","volume":"793953","author":"Fahed","year":"2012","journal-title":"International Journal of Endocrinology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2826.2009.01842.x","article-title":"Effects of gonadotrophin-releasing hormone outside the hypothalamic\u2013pituitary\u2013reproductive axis","volume":"21","author":"Skinner","year":"2009","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0260","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","article-title":"The hearth: a novel gonadotrophin-releasing hormone target","volume":"23","author":"Dong","year":"2011","journal-title":"Journal of Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0265","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0270","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1253\/circj.CJ-10-0221","article-title":"Gender differences in the ST segment \u2013 effect of androgen-deprivation therapy and possible role of testosterone","volume":"74","author":"Ezaki","year":"2010","journal-title":"Circulation Journal"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0275","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/jco.2004.22.14_suppl.4578","article-title":"The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix","volume":"22","author":"Garnick","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0280","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during ADT for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0285","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0290","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0300","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0310","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","article-title":"Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891","volume":"24","author":"Studer","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0315","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0320","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0325","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0330","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","article-title":"Androgen deprivation therapy and cardiovascular risk","volume":"29","author":"Punnen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0335","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0340","article-title":"Association of radiotherapy and hormonotherapy in locally advanced prostate cancer","volume":"April","author":"Quero","year":"2012","journal-title":"Bull Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0345","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases."},{"issue":"6","key":"10.1016\/j.critrevonc.2012.09.008_bib0350","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0355","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer a meta-analysis of randomized trials","volume":"21","author":"Nguyen","year":"2011","journal-title":"The Journal of the American Medical Association"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.09.008_bib0360","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","article-title":"Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term","volume":"82","author":"Wilcox","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ncpendmet0399","article-title":"Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone","volume":"3","author":"Engel","year":"2007","journal-title":"Nature Clinical Practice \u2013 Endocrinology and Metabolism"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0370","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU International"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0375","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","article-title":"Cardiovascular safety of Degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"Journal of Urology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0380","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of Degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"Journal of Urology"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.09.008_bib0385","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.09.008_bib0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in the older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0395","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.2010.03939.x","article-title":"Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?","volume":"74","author":"Grossmann","year":"2011","journal-title":"Clinical Endocrinology"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.09.008_bib0400","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.09.008_bib0405","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"109","author":"Nobes","year":"2012","journal-title":"BJU International"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0410","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0415","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","article-title":"Resistance exercise in men receiving ADT for prostate cancer","volume":"21","author":"Segal","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0420","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-9-210","article-title":"A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer","volume":"9","author":"Newton","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2012.09.008_bib0425","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"European Urology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.09.008_bib0430","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"European Urology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812001916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842812001916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T22:35:30Z","timestamp":1562279730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842812001916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1040842812001916"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.09.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}